Biocon share price jumps over 4% to hit 52-week high on reports of restructuring; Biologics IPO, merger under review

Biocon is in advanced discussions to restructure its wholly owned subsidiary Biocon Biologics, and is reviewing an initial ...

Biocon falls 5% after Citi double downgrades stock to 'Sell'; Check latest target price

Along with double-downgrading the stock, Citi cut Biocon’s target price to Rs 360 per share from Rs 430 per share. The latest ...

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review

Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company is in advanced talks with minority investors for a share swap, ...
MedCity News

Biocon expands portfolio & market reach with $3.3B buyout of Viatris biosimilars

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

Biocon clarifies on reports of possible merger, IPO plans for Biocon Biologics

Biocon reiterated that the internal review is ongoing. "Accordingly, the Committee constituted as aforesaid is still ...

Q2 Result Review: BSE, Fortis shine; RVNL, Biocon, CONCOR disappoint; mixed cues for Tata Power

The Q2 Result Review highlights major companies like BSE, Fortis Health, RVNL, Biocon, CONCOR, and Tata Power. BSE posted ...
Reuters

BUZZ-India's Biocon hits record; EMA to review Biocon-Mylan cancer drug

** European Medicines Agency on Thursday accepted Biocon and U.S. drugmaker Mylan's regulatory submission for proposed breast cancer drug Sign up here. ** The submission could lead to approval of the ...